|Articles|June 7, 2017

Chesapeake IRB Announces Acquisition of MaGil IRB

Chesapeake IRB-technology-enabled independent institutional review board (IRB) that serves the clinical research industry-has acquired MaGil IRB.

The acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and more staff, broadening its precense for CROs, pharma companes, and biotech companies.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Chesapeake IRB Announces Acquisition of MaGil IRB

Related Content

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention